Research Papers:

Lasp1 promotes malignant phenotype of non-small-cell lung cancer via inducing phosphorylation of FAK-AKT pathway

Xiupeng Zhang, Yang Liu, Chuifeng Fan, Liang Wang, Ailin Li, Haijing Zhou, Lin Cai, Yuan Miao _, Qingchang Li, Xueshan Qiu and Enhua Wang

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:75102-75113. https://doi.org/10.18632/oncotarget.20527

Metrics: PDF 1450 views  |   HTML 2079 views  |   ?  


Xiupeng Zhang1, Yang Liu1, Chuifeng Fan1, Liang Wang1, Ailin Li2, Haijing Zhou1, Lin Cai1, Yuan Miao1, Qingchang Li1, Xueshan Qiu1 and Enhua Wang1

1Department of Pathology, Basic Medicine Science and First Hospital of China Medical University, Shenyang, China

2Department of Radiotherapy, First Hospital of China Medical University, Shenyang, China

Correspondence to:

Yuan Miao, email: [email protected]

Keywords: Lasp1, NSCLC, proliferation and invasion, FAK, AKT

Received: December 08, 2016     Accepted: July 28, 2017     Published: August 24, 2017


Lasp1 (LIM and SH3 domain protein 1) promotes tumor proliferation and invasion in multiple cancer entities including non-small cell lung cancer (NSCLC). However, the molecular mechanism is uncertain to date. In the present study, using immunohistochemistry, we found that Lasp1 expression was significantly correlated with tumor size (P=0.005), advanced TNM stage (P=0.042), positive regional lymph node metastasis (P=0.034) and poor overall survival (P<0.001). Similar results were seen in patients with squamous cell lung carcinoma (P=0.003 for larger tumor size, P=0.017 for advanced TNM stage, P=0.003 for positive lymph node metastasis and P<0.001 for poor overall survival) but not in patients with lung adenocarcinoma (P>0.05). Proliferation and invasion assay showed that Lasp1 dramatically promoted the ability of proliferation and invasion of NSCLC cells. Subsequent western blot results revealed that Lasp1 promoted the expression of Cyclin A2, CyclinB1, and Snail, and inhibited the expression of E-cadherin. Lasp1 directly interacted with FAK and facilitated the expression of phosphorylated FAK (Tyr397) and AKT (Ser473). Incorporation of both FAK inhibitor and AKT inhibitor counteracted the upregulating expression of Cyclin A2, CyclinB1, and Snail, and downregulating expression of E-cadherin expression induced by Lasp1 overexpression. Interestingly, inhibition of FAK signaling pathway attenuated the phosphorylation of AKT, but inhibition of AKT signaling pathway did not affect the phosphorylation of FAK. In conclusion, Lasp1 facilitated tumor proliferation and invasion of NSCLC through directly binding to FAK and enhancing the phosphorylation of FAK (Tyr397) and AKT (Ser473). Lasp1 may be a novel therapeutic target in the treatment of NSCLC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20527